# Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

> **NCT00629278** · PHASE3 · UNKNOWN · sponsor: **Azienda Ospedaliero-Universitaria di Modena** · enrollment: 2500 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** aromatase inhibition therapy
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** paclitaxel
- **DRUG:** releasing hormone agonist therapy
- **DRUG:** tamoxifen citrate
- **PROCEDURE:** adjuvant therapy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00629278
- **Lead sponsor:** Azienda Ospedaliero-Universitaria di Modena
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629278, "Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00629278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*